Dormant and therefore therapy-resistant, CSCs or tumor-initiating cells are often responsible for relapse and can be characterized by the expression of numerous biomarkers such as CD44, CD24, CD29, CD49f, ALDH, CD105, CD133, or CD166, depending on the cancer type [49,50,51,52]. This evidence concerns the gene CD44 and cancer.